QPCT regulation by CTCF leads to sunitinib resistance in renal cell carcinoma by promoting angiogenesis

Sunitinib is widely used as a first-line treatment for advanced renal cell carcinoma (RCC). However, a number of patients with RCC who receive sunitinib develop drug resistance; and the biological mechanisms involved in resistance to sunitinib remain unclear. It has previously been suggested that th...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Int J Oncol
Asıl Yazarlar: Zhao, Tangliang, Zhou, Yulin, Wang, Qingyun, Yi, Xiaoming, Ge, Silun, He, Haowei, Xue, Song, Du, Bowen, Ge, Jingping, Dong, Jie, Qu, Le, Wang, Linhui, Zhou, Wenquan
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: D.A. Spandidos 2021
Konular:
Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8208629/
https://ncbi.nlm.nih.gov/pubmed/34036385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2021.5228
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller